The Diagnostic Value of Serum miRNA-221-3p, miRNA-382-5p, and miRNA-4271 in Ischemic Stroke

Wang, Yaru; Ma, Zhuolin; Kan, Pengcheng; Zhang, Biao

doi:10.1016/j.jstrokecerebrovasdis.2016.12.019

Cited by 55 publications

(38 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Correlation between serum miR-146b and proinflammatory markers Elevated plasma hs-CRP levels were reported to be positively correlated with infarct volume and NIHSS score at admission, thus, plasma hs-CRP level can reflect the severity of AIS and might be useful as a clinical tool for predicting outcome (20)(21)(22). Interesting, a moderate positive correlation existed between the expression of serum miR-146b and that of plasma hs-CRP (r=0.5231) (Fig.…”

Section: Serum Mirnas and Serum Hscrp Il-6 Levels Levels In Ais Patimentioning

confidence: 86%

“…Recently, serum exosomal MiR-9 and miR-124 are two brain-specific miRNAs and are promising biomarkers for diagnosing AIS and evaluating the degree of damage caused by ischemic injury [20] and that elevated serum expression of miR-15a, miR-16, and miR-17-5p is strongly associated with AIS [21]. Serum circulating miRNA-221-3p and miRNA-382-5p might be used as potential non-invasive biomarkers for the diagnosis of ischemic stroke [22]. However, whether these deregulated circulating miRNAs are reliable for acute ischemia stroke (AIS) risk prediction, diagnosis or outcome prediction in Chinese patients, additional study is required.…”

Section: Original Papermentioning

confidence: 99%

See 1 more Smart Citation

Upregulated Serum MiR-146b Serves as a Biomarker for Acute Ischemic Stroke

Chen

Wang

Huang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Stroke is a major cerebrovascular disease threatening human health and life with high morbidity, disability and mortality. It is aimed to find effective biomarkers for the early diagnosis on stroke. Methods: The expressions of 17 previously reported strokeassociated miRNAs were measured using quantitative RT-PCR and the expressions of plasma high-sensitivity C reactive protein (hs-CRP) and serum interleukin 6 (IL-6), the proinflammation markers in brain injury, were examined using enzyme-linked immunosorbent assay in 128 acute ischemic stroke (AIS) patients and control group.

show abstract

Section: Serum Mirnas and Serum Hscrp Il-6 Levels Levels In Ais Patimentioning

confidence: 86%

Section: Original Papermentioning

confidence: 99%

Upregulated Serum MiR-146b Serves as a Biomarker for Acute Ischemic Stroke

Chen

Wang

Huang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…There is a growing body of evidence pointing to potential usefulness of serum miRNA as a diagnostic and therapeutic target in neurological conditions. Besides epilepsy, serum miRNAs were evaluated in MS, where diminished expression of miR-572 was observed in MS patients [77], in migraine patients, where miR-382-5p were increased in pain-free period [78], and in ischemic stroke, where miRNA-221-3p and miRNA-382-5p serum concentrations were elevated compared to healthy control [79]. Furthermore, miRNAs are thought to be a useful marker for diagnosis and monitoring of progression of neurodegenerative disorders like Alzheimer and Parkinson's diseases [80,81].…”

Section: Mirnasmentioning

confidence: 99%

Looking for novel, brain-derived, peripheral biomarkers of neurological disorders

Chmielewska

Szyndler

Makowska

et al. 2018

Neurologia i Neurochirurgia Polska

View full text Add to dashboard Cite

The role of blood brain barrier (BBB) is to preserve a precisely regulated environment for proper neuronal signaling. In many of the central nervous system (CNS) pathologies, the function of BBB is altered. Thus, there is a necessity to evaluate a fast, noninvasive and reliable method for monitoring of BBB condition. It seems that revealing the peripheral diagnostic biomarker whose release pattern (concentration, dynamics) will be correlated with clinical symptoms of neurological disorders offers significant hope. It could help with faster diagnosis and efficient treatment monitoring. In this review we summarize the recent data concerning exploration of potential new serum biomarkers appearing in the peripheral circulation following BBB disintegration, with an emphasis on epilepsy, traumatic brain injury (TBI) and stroke. We consider the application of well-known proteins (S100β and GFAP) as serum indicators in the light of recently obtained results. Furthermore, the utility of molecules like MMP-9, UCHL-1, neurofilaments, BDNF, and miRNA, which are newly recognized as a potential serum biomarkers, will also be discussed.

show abstract

“…Chen, Yang, Cheng, Xue, & Chen, 2017), coronary artery disease (Fichtlscherer, et al, 2010;Fujii, Sugiura, Dohi, & Ohte, 2016;X. Sun, Zhang, et al, 2012), atherosclerosis (Feinberg & Moore, 2016;Hosin, Prasad, Viiri, Davies, & Shalhoub, 2014;Menghini, Stohr, & Federici, 2014), stenosis (Dolz, et al, 2017;Jansen, et al, 2017), acute heart failure (Ovchinnikova, et al, 2016), congestive heart failure (Fukushima, Nakanishi, Nonogi, Goto, & Iwai, 2011;Tijsen, et al, 2010), ischemic stroke (Sorensen, Nygaard, & Christensen, 2016;Y. Wang, Ma, Kan, & Zhang, 2017) and systemic lupus erythematosus (SLE) (J. Q.…”

Section: Evidence For a Functional Role Of Mirnas In The Hemostatic Smentioning

confidence: 99%

A novel rationale for targeting FXI: Insights from the hemostatic miRNA targetome for emerging anticoagulant strategies

Nourse

Danckwardt

2018

Preprint

View full text Add to dashboard Cite

The treatment and prevention of thrombosis is currently under a period of rapid change with the replacement of traditional anticoagulant vitamin K antagonists with direct oral anticoagulants (DOACs), which specifically target factors FXa or FIIa.Nevertheless therapeutic targeting of blood coagulation is an inherently difficult task as it interferes with the delicate balance of pro-and anticoagulant activities. Although anticoagulants are employed in millions of thrombophilic patients worldwide each year, for a growing population with comorbidities who exhibit an increased risk of bleeding with DOAC treatment satisfying therapeutic options are still lacking and the quest for novel therapeutics continues.Recently the targeting of factors FXI and FXII have emerged as new therapeutic strategies. As these factors play an important roles in thrombosis, however are more or less functionally dispensable for hemostasis, they may potentially overcoming the functional obstacle of treating or preventing thrombosis without affecting hemostasis.A key question in following up this approach is which of these two factors is likely to be the more reliable target? Here we present and discuss a hitherto unrecognized rationale for the therapeutic targeting of FXI. This is based on mimicking endogenous FXI gene expression control by therapeutic delivery of miRNA mimics.Studies are urgently needed to test this therapeutic principle in a clinical setting. This is particularly applicable in hemostaseology where monitoring of therapeutic effects remains a daily routine and thus assessment of the efficacy and safety of such therapeutic components could be simply implemented ushering in a novel therapeutic era with broad applicability.

show abstract

The Diagnostic Value of Serum miRNA-221-3p, miRNA-382-5p, and miRNA-4271 in Ischemic Stroke

Cited by 55 publications

References 25 publications

Upregulated Serum MiR-146b Serves as a Biomarker for Acute Ischemic Stroke

Upregulated Serum MiR-146b Serves as a Biomarker for Acute Ischemic Stroke

Looking for novel, brain-derived, peripheral biomarkers of neurological disorders

A novel rationale for targeting FXI: Insights from the hemostatic miRNA targetome for emerging anticoagulant strategies

Contact Info

Product

Resources

About